The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk ... Patients with advanced or metastatic breast cancer had a recommended oral dose of 600 mg tablets that were received once ...